1. Home
  2. AAOI vs SNDX Comparison

AAOI vs SNDX Comparison

Compare AAOI & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Applied Optoelectronics Inc.

AAOI

Applied Optoelectronics Inc.

HOLD

Current Price

$29.94

Market Cap

1.6B

Sector

Technology

ML Signal

HOLD

Logo Syndax Pharmaceuticals Inc.

SNDX

Syndax Pharmaceuticals Inc.

HOLD

Current Price

$20.82

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AAOI
SNDX
Founded
1997
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.6B
1.7B
IPO Year
2013
2016

Fundamental Metrics

Financial Performance
Metric
AAOI
SNDX
Price
$29.94
$20.82
Analyst Decision
Buy
Strong Buy
Analyst Count
6
12
Target Price
$33.60
$36.92
AVG Volume (30 Days)
5.1M
2.1M
Earning Date
11-06-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$421,712,000.00
$111,304,000.00
Revenue This Year
$85.86
$620.14
Revenue Next Year
$64.48
$115.42
P/E Ratio
N/A
N/A
Revenue Growth
101.25
595.65
52 Week Low
$9.71
$8.58
52 Week High
$41.27
$21.22

Technical Indicators

Market Signals
Indicator
AAOI
SNDX
Relative Strength Index (RSI) 54.12 67.42
Support Level $24.83 $20.00
Resistance Level $37.05 $21.22
Average True Range (ATR) 2.57 0.93
MACD 1.02 0.02
Stochastic Oscillator 54.57 85.90

Price Performance

Historical Comparison
AAOI
SNDX

About AAOI Applied Optoelectronics Inc.

Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.

About SNDX Syndax Pharmaceuticals Inc.

Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Share on Social Networks: